-=Madrigal Pharmaceuticals (MDGL) achieves primary endpoint in Phase 2 Clinical Trial

Madrigal Pharmaceuticals MGL-3196 achieves primary endpoint in patients with biopsy-proven non-alcoholic steatohepatitis  
The company announced positive top-line results from a Phase 2 clinical trial in patients with biopsy-proven non-alcoholic steatohepatitis . In this trial, MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) -selective agonist, demonstrated statistically significant results for the primary endpoint, the percent change in hepatic fat versus placebo as measured by MRI-PDFF, a non-invasive imaging test.